Supernus Pharmaceuticals | Innovating CNS Treatments
Supernus, a biopharmaceutical company, develops CNS disease treatments. Transforming patient care with cutting-edge therapies and strategic partnerships.
Supernus Announces FDA Approval of ONAPGO ... - Markets Insider
3 days ago · Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
U.S. FDA approves Supernus' drug-device combination for …
3 days ago · The drug-device combo, which Supernus acquired through a $530-million deal, opens new tab in 2020, continuously delivers the drug apomorphine under the skin, providing a more convenient method of ...
Supernus Announces FDA Approval of ONAPGO™ (apomorphine …
3 days ago · Supernus Pharmaceuticals, Inc. ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s disease. ONAPGO ...
Supernus wins FDA approval for Parkinson’s pump on fourth try
1 day ago · Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of Parkinson’s disease. Supernus’ regulatory path for Onapgo has been marked by multiple setbacks over nearly five years, with the Food and Drug Administration (FDA) rejecting three prior applications before securing approval.
About Us - Supernus
At Supernus, we develop innovative products that help treat neurological and psychiatric conditions. It's about more than science and research, though. It's about the real impact these products have on people by helping to improve their health.
Supernus Pharmaceuticals Announces FDA Approval of ONAPGO, …
3 days ago · Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Supernus CNS Products | Neurology & Psychiatry Conditions
At Supernus, we create innovative products to treat neurology and psychiatry conditions, focusing on their real impact in improving people's health.
Supernus Announces Promising Data from Open-Label Phase 2a …
Oct 17, 2024 · Supernus Pharmaceuticals, Inc. Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms. SPN-820 was well-tolerated with few adverse events
Supernus' Parkinson's pump Onapgo finally lands FDA approval
3 days ago · Supernus’ Apokyn contributed $19.9 million to the company’s total sales over the third quarter of 2024. In 2023, the drug pulled in $75.1 million in full-year sales.
- Some results have been removed